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Neurofibromatosis type 1 syndrome (NF1) is caused by 
mutations in the NF1 gene. Availability of new sequen-
cing technology prompted us to search for an alterna-
tive method for NF1 mutation analysis. Genomic DNA 
was isolated from saliva avoiding invasive sampling. 
The NF1 exons with an additional 50bp of flanking in-
tronic sequences were captured and enriched using the 
SeqCap EZ Choice Library protocol. The captured DNA 
was sequenced with the Roche/454 GS Junior system. 
The mean coverages of the targeted regions were 41× 
and 74× in 2 separate sets of samples. An NF1 mutation 
was discovered in 10 out of 16 separate patient samples. 
Our study provides proof of principle that the sequence 
capture methodology combined with high-throughput 
sequencing is applicable to NF1 mutation analysis. Deep 
intronic mutations may however remain undetectable, 
and change at the DNA level may not predict the outcome 
at the mRNA or protein levels. Key words: mutation ana-
lysis; neurofibromatosis type 1; next-generation sequen-
cing; pyrosequencing; saliva DNA; target enrichment.
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Neurofibromatosis type 1 (NF1) is an autosomal dominant 
syndrome with a prevalence of 1:3500. The diagnosis of 
NF1 is usually based on clinical findings outlined in the 
NIH criteria (1). Most important of these, café-au-lait 
macules, skinfold freckles and neurofibromas, are readily 
visible on skin. However, clinicians often face situations 
where there are some NF1 symptoms but not sufficient for 
clinical diagnosis. Since NF1 is a multiorgan disease with 
frequent complications from various organ systems, the 
correct early diagnosis is essential. During the 21st century, 
molecular diagnostics of NF1 has become possible and in-
creasingly important in NF1 diagnosis. Mutation analysis 
of NF1 has proven valuable especially in young children 
who may only partially fulfill the clinical criteria. The same 
holds true for adults with atypical clinical presentation.
The NF1 gene, located on 17q11.2. is challenging to 
sequence due to its large size and numerous exons. The 
gene spans ~280 kb of genomic DNA, comprising 57 
constitutive and at least 3 alternatively spliced exons. To 
date, over 1,400 different pathogenic mutations of the 
NF1 gene have been published (2). The mutations are 
dispersed throughout the gene and represent various mu-
tation types, including insertions, deletions, substitutions 
and duplications. Microdeletions refer to large deletions 
which cover the entire NF1 gene and a number of flan-
king genes. The type 1 NF1 microdeletion is the most 
frequent encompassing 1.4 Mb. The type 2 microdeletion 
spanning 1.2 Mb and type 3 spanning 1.0 Mb are less 
frequent (3–6). Chromosomal rearrangements affecting 
one or several exons have also been observed (7). In ad-
dition, the human genome contains NF1 pseudogenes in 
chromosomes 2, 12, 14, 15, 18, 21 and 22 (8–12), which 
interfere with gDNA-based sequencing methods.
High-throughput methods can yield the sequence of the 
whole genome in a single analysis, but at costs too high 
for today’s routine diagnostics. Therefore, targeting the 
genomic area of interest allows analysing several samples 
in one run and produces less data for analysis compa-
red to whole genome sequencing. To our knowledge, 
there is only one report assessing the feasibility of next 
generation sequencing for the targeted resequencing of 
the NF1 gene. Chou et al. (13). analysed 2 samples with 
known NF1 mutations using DNA sequence capture and 
enrichment by microarray followed by pyrosequencing.
At present, molecular diagnostics of NF1 utilise Sanger 
sequencing with either mRNA and/or genomic DNA 
(gDNA) as the starting material. The traditional methods 
can yield excellent results but are laborious and time-
consuming. Furthermore, mRNA-based methods usually 
require fresh blood or tissue sampling. The rapid develop-
ment of novel sequencing techniques has created visions 
for a cost-effective and non-invasive method without 
compromising sensitivity. This is a particularly important 
pursuit since the availability of information on NF1 has 
expanded and the demand for molecular diagnostics 
among patients and physicians is continuously increasing. 
The purpose of the present study was to develop an NF1 
mutation analysis method, which does not require invasive 
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sampling and which utilises new sequencing technology. 
A total of 16 unrelated NF1 patients were investigated.
PATIENTS AND METHODS (see Appendix S11)
RESUlTS
Sample quality, sequence capture and sequencing
The gDNA yield of 2.7–28 µg from the saliva samples 
was sufficient for mutation analysis. The variation in the 
amount mostly depended on the original volume of sa-
liva. Gel electrophoresis (Fig. S11) showed > 10 kb bands 
consistent with intact gDNA. The sequence capture 
was successful, as estimated by qPCR using 4 internal 
control sequences, complying with the manufacturer’s 
guidelines. Both sequencing runs passed the quality 
criteria set by the manufacturer. 
Mapping and sequencing coverage
In the set A of 10 samples, the number of reads per 
sample was between 8,023 and 16,783. In the set B of 6 
samples, 13,984–29,886 reads were obtained per sample. 
The mean read length across sample sets was 405 bp. 
For the sets of A and B, the mean proportion of reads 
that were mapped to the human genome with Bowtie 2 
was 96% and 98%, respectively. The number of reads 
for each sample is listed in Table SI1. The distribution 
of reads into different chromosomes in the Bowtie 2 
mapping is shown in Table I. The chromosomes with 
the most off-target reads are locations of known NF1 
pseudogenes. Approximately 32–35% of the reads were 
mapped to the NF1 gene on chromosome 17. 
The overview of the sequencing results is listed in 
Table SII1. The mean coverage of targeted regions was 
41× and 74× for the sets A and B, respectively. Exon 1 
was covered poorly in both sets (Fig. S21), with mean 
coverages of 3× and 6×. Low coverage in the first exon 
of genes has been previously observed, possibly due to 
a high GC content (30). This explanation is relevant also 
in our experiment, as the GC content of the NF1 exon 
1 is 71%, while the mean across all NF1 exons is 42%.
Mutations
The GATK UnifiedGenotyper program reported 1,420 
and 944 preliminary variants in the NF1 gene in the sets 
of A and B, respectively. The filtering, described in detail 
in Patients and Methods, resulted in the identification of 
a total of 63 variants as potential mutations in the sam-
ple sets of A and B. Seven variants which were listed in 
dbSNP database were evaluated individually and their 
pathogenicity was excluded. In addition, 2 out of the 7 
single nucleotide polymorphisms were included in the 
Finnish database (29). The remaining 39 and 17 variants 
in sets A and B were assessed individually with respect 
to homopolymer-related sequencing errors and lack of 
evidence from reads originating from both the sense and 
antisense strands. Ten homopolymer-related regions with 
a potential mutation were selected for Sanger-sequencing 
(Fig. S3A1). These proved to represent false positives.
Ten mutations were identified as putative disease-cau-
sing mutations (Table II). These included 6 substitutions, an 
insertion and 3 small deletions. Five previously un known 
mutations of patients S47, E66, E71, E396, and S97 were 
confirmed with Sanger sequencing (Fig. S31). One pre-
viously known mutation in a control sample (patient E39) 
was excluded in the filtering due to low coverage. However, 
visual inspection of this area revealed the mutation in 2 out 
of 9 reads. The known microdeletion of a control sample 
could not be detected. Mutations of 4 patients thus remai-
ned unsolved. To learn why these were not revealed, the 4 
DNA samples were sent to an internationally recognised 
diagnostic laboratory, which sequenced all NF1 exons plus 
30 bp intronic sequence and carried out MLPA (Multiplex 
Ligation-dependent Probe Amplification) analysis. These 
analyses revealed one additional mutation in patient S49 
(c.844C>T, p.Gln282X) in NF1 exon 6. In our experiment, 
this area of the sample S49 had low coverage of only 11 
reads and the mutation was visible in one read and thus 
could not raise suspicion of a pathogenic mutation. Three 
mutations remained undiscovered by our protocol, and by 
an established international diagnostic laboratory.
DISCUSSION
Our study of DNA samples from 16 unrelated NF1 
patients provides proof of principle that the sequence 
capture methodology combined with high-throughput 
sequencing is applicable to NF1 mutation analysis. 
DNA sampling using a saliva collection kit yielded high-
quality DNA without invasive sampling. The samples 
could be collected by the patients at home, and because 
of the stability of the samples, they could easily be ship-
ped to the laboratory without need for cold storage. The 
quality of DNA was evaluated by running the samples 
on agarose gels, which showed single bands larger than 
10 kb. Saliva samples have more commonly been used 
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1843
Table I. Percentage of reads (out of all mapped reads) mapped to 
chromosomes which contain neurofibromatosis type 1 pseudogenes 
or the NF1 gene (Chr 17)
Chromosome
Set A (10 samples) 
%
Set B (6 samples) 
% 
Chr 2 5.70 6.97
Chr 12 1.48 2.15
Chr 14 14.28 15.68
Chr 15 24.32 23.82
Chr 17 35.02 31.92
Chr 18 2.50 1.94
Chr 21 2.46 1.94
Chr 22 13.92 15.28
Other chromosomes 0.32 0.30
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in forensic medicine as a source for DNA (31), and the 
use of saliva in high throughput sequencing has been 
elucidated in a recent publication (32). Although the 
NF1 mutation analysis method described here is not yet 
validated for clinical application, it paves the way for 
new approaches in NF1 mutation analysis. 
The sequence capture method was sensitive in enriching 
the NF1 exons, with the exception of the exon number 1. 
It should be noted that sequencing of the first exon of the 
NF1 gene is challenging also in RNA-based protocols (33). 
In cases where a mutation is not found in the other exons, 
exon 1 needs to be Sanger sequenced. However, exon 1 is 
not frequently mutated, since only 6 mutations of the NF1 
gene have been described to date. The sequence capture is 
an independent module of the mutation analysis, allowing 
sequencing with different platforms. In the current study, the 
Roche GS Junior sequencing device was used. It utilises the 
same 454 pyrosequencing technology as the 454 GS FLX 
device, which is a widely used high-throughput sequencing 
platform. For the current application, the 454 GS Junior was 
selected because it has a smaller total capacity, which makes 
it more applicable to the sequencing of smaller targets such 
as a single gene instead of the whole genome. 
In general, the quality of the sequencing reads was high in 
our protocol, as shown by the correct reading of the control 
sequences supplied by the manufacturer. Sequencing errors 
in homopolymer regions were observed in our data, which 
is a well-recognised problem of pyrosequencing. To deal 
with this problem, we have compared the sequences of the 
homopolymeric regions between different samples. The 
reads from homopolymeric regions tend to resemble each 
other in normal samples while real mutations may look 
different. Thus, putative mutations in homopolymers need 
to be individually examined, compared to the results for the 
corresponding position in other samples, and if mutation is 
still suspected, it needs to be verified by Sanger sequencing. 
(Fig. S3A1).
Pseudogenes are considered as a challenge in genetic 
testing and were expected to cause problems also in this 
method. However, in our approach the correct mapping of 
the reads either to pseudogenes or the NF1 gene appeared 
successful. This may be due to the relatively long reads, 
approximately 400 bp, produced by the sequencing method 
used. No doubt, the sequence capture methodology suffers 
from the existence of pseudogenes, in that their sequences 
are also captured along with the NF1 gene sequence. This 
reduces the mean coverage of the NF1 exons. However, 
none of the variants that passed the filters were due to 
pseudogene sequences falsely mapping to the NF1 gene. 
Thus, the variant calling was not adversely affected by the 
existence of pseudogenes, and based on what we have seen, 
there is no reason to believe that the mapping program used 
in the analysis would fail in mapping reads correctly to 
either the NF1 gene, or to its pseudogenes. Therefore, we 
did not experience problems with the pseudogenes in the 
data analysis, even though they were originally captured in 
the sequence capture step. Ta
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In the NF1 mutation analysis presented here, substitu-
tions and short insertions/deletions were readily observed 
in the sequencing data in areas where the coverage was 
at least 20×. If this coverage was used with variant fre-
quency between 30–70%, about 97% of heterozygous 
variants could be found, as calculated according to De 
Leeneer et al. (25). However, since the coverage of 20× 
was not reached in all nucleotides, the sensitivity could 
be increased by lowering the threshold of frequency from 
30% to 20%. This in turn may increase the number of 
false positives. The best way to increase both sensitivity 
and specificity would be to increase coverage by sequen-
cing a smaller number of samples per run (25). To avoid 
missing of known pathogenic mutations because of low 
coverage, comparison of the variants with previously 
published mutations will be utilised in the future. Using 
the mutation information in databases is becoming an 
increasingly powerful tool since the number of known 
pathogenic mutations is increasing. 
A putative mutation was discovered in 10 samples out of 
the total 16. Out of the 7 previously analyzed mutations, 5 
were readily evident in the data. One control mutation was 
observed in visual analysis, but was excluded in the filtering 
due to a total coverage of less than 20×. The known microde-
letion could not be detected and in cases when no mutations 
are found, we recommend combining an MlPA analysis and 
Sanger sequencing of targets with low coverage. In 4 cases, 
an NF1 mutation could not be found. Mutation analysis was 
then carried out in an internationally recognised diagnostic 
laboratory and this approach, including MlPA, revealed one 
more mutation which was present in our data in a single read 
out of 11. However, the NF1 mutation could not be found 
in 3 cases. It should be noted that these 3 patients clearly 
fulfilled the NF1 diagnostic criteria for NF1. One of them 
may represent a case of somatic mosaicism for NF1 because 
of the clinical features of the patient. In somatic mosaicism, 
the NF1 mutation is not likely to be found in blood or saliva 
samples. The 3  mutations remaining undetected may also 
be deep intronic, or reside outside of the NF1 gene.
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